Given the potential advantages of this combination, several randomized controlled trials (RCTs) have been conducted to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in conjunction with anti-angiogenic agents in patients with unresectable HCC. Here, CD274 is linked to hepatocellular carcinoma.